Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes

American Journal of Hematology

Volumn 89, Issue 8, 2014, Pages 809-812

  Komrokji, Rami S ^a   Padron, Eric ^a   Yu, Daohai ^a   Fulp, William J ^a   Rodriguez, Yuraima ^a   Tinsley, Sara ^a   List, Alan F ^a   Lancet, Jeffrey E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Azanucleosides failure; Erlotinib; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ERLOTINIB;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PAIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DESQUAMATION; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY FAILURE; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SEPSIS; SUDDEN DEATH; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AZANUCLEOSIDES FAILURE; ERLOTINIB; MYELODYSPLASTIC SYNDROMES;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84904401635     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23749     Document Type: Article

References (17)

1. Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am;24:443-457.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
4. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116:3830-3834.
5. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-3327.
6. Duong VH, Lin K, Reljic T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk 2013;13:711-715.
7. Boehrer S, Ades L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008;111:2170-2180.
8. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007;110:1079-1080.
9. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008;26:3645-3646.
10. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
11. Raza A, Greenberg PL, Olnes MJ, et al. Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological effects in patients with myelodysplastic syndrome and correlation with overall survival. ASH Annual Meeting Abstracts 2012;118:3822.
12. Duong VH, Jaglal MV, Zhang L, et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leukemia Res 2013;37:300-304.
13. Komrokji RS, Raza A, Lancet JE, et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013;162:517-524.
14. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011;38:682-692.
15. Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011;117:1463-1469.
16. Lainey E, Wolfromm A, Marie N, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013;32:4331-4342.
17. Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. 2012.